Contact this trialFirst, we need to learn more about you.
SMN2 Splicing Modifier
Risdiplam for Spinal Muscular Atrophy
Recruiting3 awardsPhase 4
Little Rock, Arkansas
This trial aims to test the effectiveness and safety of risdiplam as an early treatment for young children with spinal muscular atrophy who have a specific genetic makeup.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.